Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hebanthe eriantha methanolic extract is a **botanical research extract** prepared from the roots of *Hebanthe eriantha*, also known as suma or Brazilian ginseng. It is not a defined single-entity pharmaceutical but a complex plant-derived mixture reported to contain constituents such as pfaffosides and pfaffic acid. In preclinical academic studies, the extract showed **in vitro antiproliferative activity** against human colon cancer HCT116 cells and mouse breast tumor 4T1 cells, and **antibacterial activity** against *Staphylococcus aureus* and *Proteus vulgaris*. Its mechanism of action has not been established at a defined molecular target level; any observed effects are likely due to multi-component phytochemical activity rather than a validated, target-specific drug mechanism. There is no clear evidence of commercial clinical development, branding, or pharmaceutical manufacturing for this specific extract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hebanthe eriantha methanolic extract.